ProCE Banner Activity

CE / CME

Biomarkers and Molecular Testing of NSCLC: First Step in Choosing Optimal Systemic Therapy

Interactive Video Lecture

Systemic therapy for advanced non-small cell lung cancer (NSCLC) is one of the most rapidly evolving areas in oncology practice. With rapid advancement in identifying druggable mutations and developing therapies to target them, healthcare professionals in oncology practice are challenged to remain current on molecular testing, guidelines, and appropriate therapy choices. Predictive biomarkers are a key consideration in treatment decision-making in NSCLC. In this video lecture, an expert provides information on predictive biomarkers and how biomarkers guide optimal use of targeted- and immunotherapies in the care of patients with NSCLC, and reviews adverse events associated with this diverse set of therapies and their management.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit
Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: January 31, 2022

Expiration: January 30, 2023

Begin Activity

Share

Faculty

Beth Sandy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Acknowledgement

This program was cosupported by educational grants from Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe key biomarkers in advanced NSCLC

  • Implement recommended biomarker and molecular testing in patients presenting with advanced NSCLC

  • Apply strategies to match patients with appropriate biomarker-driven therapy choices

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Ms Sandy: fees for non-CME/CE services: Amgen, AstraZeneca, Jazz, Merck, Takeda.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Ms Sandy as noted above.

CME Info

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: January 31, 2022
Expiration date: January 30, 2023

Format

Interactive video lecture

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 30, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.